title: Evaluating Positron Emission Tomography Use in Differentiated Thyroid Cancer.
abstract: BACKGROUND
  Using the Surveillance, Epidemiology, and End Results-Medicare database, a substantial increase was found in the use of positron emission tomography (PET) scans after 2004 in differentiated thyroid cancer (DTC) patients. The reason for the increased utilization of the PET scan was not clear based on available the data. Therefore, the indications for and outcomes of PET scans performed at an academic institution were evaluated.
  
  
  METHODS
  A retrospective cohort study was performed of DTC patients who underwent surgery at the University of Michigan Health System from 2006 to 2011. After identifying patients who underwent a PET scan, indications, rate of positive PET scans, and impact on management were evaluated. For positive scans, the location of disease was characterized, and presence of disease on other imaging was determined.
  
  
  RESULTS
  Of the 585 patients in the cohort, 111 (19%) patients had 200 PET scans performed for evaluation of DTC. Indications for PET scan included: elevated thyroglobulin and negative radioiodine scan in 52 scans (26.0%), thyroglobulin antibodies in 13 scans (6.5%), rising thyroglobulin in 18 scans (9.0%), evaluation of abnormality on other imaging in 22 scans (11.0%), evaluation of extent of disease in 33 scans (16.5%), follow-up of previous scan in 57 scans (28.5%), other indications in two scans (1.0%), and unclear indications in three scans (1.5%). The PET scan was positive in 124 studies (62.0%); positivity was identified in the thyroid bed on 25 scans, cervical or mediastinal lymph nodes on 105 scans, lung on 28 scans, bone on four scans, and other areas on 14 scans. Therapy following PET scan was surgery in 66 cases (33.0%), chemotherapy or radiation in 23 cases (11.5%), observation in 110 cases (55.0%), and palliative care in one case (0.5%). Disease was identifiable on other imaging in 66% of cases. PET scan results changed management in 59 cases (29.5%).
  
  
  CONCLUSIONS
  In this academic medical center, the PET scan was utilized in 19% of patients. Indications for the PET scan included conventional indications, such as elevated thyroglobulin with noniodine avid disease, and more controversial uses, such as evaluation of extent of disease or abnormalities on other imaging tests. PET scan results changed management in about 30% of cases.
authors.affiliation: 1 Division of Metabolism, Endocrinology, and Diabetes, University of Michigan , Ann Arbor, Michigan.
authors.forename: Jaime L
authors.initials: JL
authors.lastname: Wiebel
authors.affiliation: 1 Division of Metabolism, Endocrinology, and Diabetes, University of Michigan , Ann Arbor, Michigan.
authors.forename: Nazanene H
authors.initials: NH
authors.lastname: Esfandiari
authors.affiliation: 1 Division of Metabolism, Endocrinology, and Diabetes, University of Michigan , Ann Arbor, Michigan.
authors.forename: Maria
authors.initials: M
authors.lastname: Papaleontiou
authors.affiliation: 2 Division of Hematology/Oncology, University of Michigan , Ann Arbor, Michigan.
authors.forename: Francis P
authors.initials: FP
authors.lastname: Worden
authors.affiliation: 1 Division of Metabolism, Endocrinology, and Diabetes, University of Michigan , Ann Arbor, Michigan.
authors.forename: Megan R
authors.initials: MR
authors.lastname: Haymart
mesh_terms: D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes / Q000737:chemistry; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D012189:Retrospective Studies; D018426:SEER Program; D013954:Thyroglobulin / Q000097:blood; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging*; D016896:Treatment Outcome; D014481:United States
chemical_list: D007457:Iodine Radioisotopes; D013954:Thyroglobulin